retatrutide phase 2 trial new england journal of medicine ๐จ Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. ๐ Mean body weight change at 80 weeks: โฌ๏ธ In the ATTAIN-1 phase 3,
Pay in 4 interest-free payments of $5.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 23 - Aug 28






























